Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
NCT ID: NCT05107375
Last Updated: 2023-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
299 participants
INTERVENTIONAL
2021-09-03
2022-03-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Test groups:A total of 300 cases were enrolled. 240 patients in 18-59 years old group, 60 patients in ≥60 years old group. There were 150 cases in group A, 120 cases in 18-59 years old group, and 30 cases in ≥60 years old group. There were 150 cases in group B, 120 cases in 18-59 years old group and 30 cases in ≥60 years old group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.
NCT06342349
Intramuscular CodaVax-H1N1 in Healthy Adults
NCT05223179
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
NCT06178991
Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years
NCT01560793
Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)
NCT02249221
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intervention:
Group A: one dose of influenza virus split vaccine and one dose of recombinant Novel coronavirus vaccine (CHO cells) in the contralateral arm on day 0, the second dose of recombinant Novel coronavirus vaccine (CHO cells) on day 30, and the third dose of recombinant Novel coronavirus vaccine (CHO cells) on day 60 were given intramuscularly in the upper arm deltoid muscle.
Group B: the first dose of recombinant Novel coronavirus vaccine (CHO cells) was administered on day 0, the second dose of recombinant Coronavirus vaccine (CHO cells) on day 30, the first dose of influenza virus lysate vaccine on day 44, and the third dose of recombinant Coronavirus vaccine (CHO cells) on day 60.
One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein. Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
Immunogenicity observation:
Evaluation of immunogenicity In group A, about 5.0mL of venous blood was collected for immunogenicity test before the first dose of vaccine, before the second dose of Novel Coronavirus vaccine (CHO cells) and 14 days after the third dose of recombinant Novel Coronavirus vaccine (CHO cells).
In group B, about 5.0mL of venous blood was collected for immunogenicity test before the first dose of vaccine and 14 days after the third dose of recombinant Novel Coronavirus vaccine (CHO cells).
Safety assessment
AE and SAE
All adverse events (AE), all AE at 30 min after each dose of recombinant Novel Coronavirus vaccine (CHO cells) and influenza vaccine, all AE at 0-7 days (both solicitation and non-solicitation AE) and all AE at 8-30 days (non-solicitation AE) were collected; All SAE were collected from the first dose to 1 month after full immunization.
Solicitation AE\[the following events occurring within 7 days after vaccination with recombinant Novel Coronavirus vaccine (CHO cells)\] :
Inoculation site (local) AE: pain, swelling, induration, redness, rash, pruritus Vital signs: fever Non-inoculated site (whole body) AE: headache, fatigue/fatigue, diarrhea, nausea, vomiting, muscle pain (non-inoculated site), acute allergic reaction, cough
Vital signs and physical examination
All subjects shall have their axillary body temperature checked daily during the screening period, before the subsequent dose of recombinant Novel Coronavirus vaccine (CHO cells), and within 7 days after each dose of recombinant Novel Coronavirus vaccine (CHO cells); Subjects in group B will have their armpit temperature measured before influenza vaccination (the day of vaccination).
All subjects underwent physical examination (skin and cardiopulmonary auscultation) and blood pressure measurement during the screening period.
Pregnancy event
Urine pregnancy test should be performed on women of childbearing age before each dose of recombinant Novel Coronavirus vaccine (CHO cells); Women of childbearing age in group B should have a urine pregnancy test prior to influenza vaccination.
Pregnancy events occurring within 1 month from the first dose of vaccine to full immunization were collected.
ADE/VED risk monitoring
After vaccination (at least 1 dose of trial vaccine) (at each visit), subjects will be reminded to contact the investigator in case of fever and/or respiratory symptoms (e.g., dyspnea, sore throat, etc.), suspected or confirmed cases of COVID-19 occurring during the study period. If the subjects are suspected or confirmed to be infected with SARS-COV-2 during the trial period, they should go to a local designated hospital for diagnosis and treatment. A detailed case-by-case investigation is required for confirmed cases. In the event of severe COVID-19 infection or death, an expert meeting should be held to evaluate ADE/VED.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Population Ⅰ
One dose of influenza virus split vaccine and one dose of recombinant Novel coronavirus vaccine (CHO cells) were given in the contralateral arm on day 0, the second dose of recombinant Novel coronavirus vaccine (CHO cells) on day 30 and the third dose of recombinant Novel coronavirus vaccine (CHO cells) on day 60, all in the upper arm deltoid muscle.
Tetravalent influenza virus lysis vaccine
Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
Recombinant new coronavirus vaccine (CHO cell) group
One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
Population Ⅱ
The first dose of recombinant Novel Coronavirus vaccine (CHO cells) was given on day 0, the second dose of recombinant Coronavirus vaccine (CHO cells) on day 30, the first dose of influenza virus lysate vaccine on day 44, and the third dose of recombinant Coronavirus vaccine (CHO cells) on day 60, all in the upper arm deltoid muscle.
Tetravalent influenza virus lysis vaccine
Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
Recombinant new coronavirus vaccine (CHO cell) group
One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tetravalent influenza virus lysis vaccine
Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
Recombinant new coronavirus vaccine (CHO cell) group
One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The subjects voluntarily agree to participate in the study and sign the informed consent to understand and comply with the requirements of the study protocol;
3. Fertile men and women of reproductive age did not have sex from day 1 of the last menstrual cycle to day 1 of the study, or did not have sex using effective contraceptive methods and did not experience contraceptive failure (examples of contraceptive failure include male condom rupture during sex). At the same time, subjects agreed to take effective contraceptive measures for 1 month from the signing of informed consent to the full immunization and no pregnancy plans during this period.
Exclusion Criteria
2. SARS virus history;
3. For those with fever, axillary temperature ≥37.3℃ on the day of inclusion;
4. A past history of severe allergy to any vaccine, or to the active ingredient of the test vaccine, any inactive ingredient, or substance used in the manufacturing process, including aluminum preparations, egg protein, neomycin, formaldehyde, tritonX-100, such as: Acute anaphylaxis, dyspnea, angioneurotic edema, etc., or allergies during previous vaccinations of the same kind;
5. Patients with uncontrolled epilepsy and other serious neurological diseases (e.g., transverse myelitis, Guillain-Barre syndrome, demyelinating disease, etc.);
6. Patients with acute diseases, or acute episodes of chronic diseases, or uncontrolled severe chronic diseases (such as hypertension that cannot be controlled by drugs, systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg);
7. Patients at the active stage of autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, sjogren's syndrome, etc.), patients with congenital or acquired immune deficiency, HIV infection with opportunistic infection or uncontrolled malignant tumor, lymphoma and leukemia;
8. No spleen, or splenic operation history;
9. Received immunomodulators within 6 months, such as immunosuppressive doses of glucocorticoids (dose reference: equivalent to prednisone 20mg/ day, over a week); Or monoclonal antibodies; Or thymosin; Or interferon; However, topical use (such as ointments, eye drops, inhalants or nasal sprays) is allowed;
10. Has received blood or blood-related products, including immunoglobulin (including rabies immunoglobulin and tetanus immunoglobulin), within 3 months prior to experimental vaccine vaccination; Or planned use of the experimental vaccine within 1 month of vaccination;
11. If subunit vaccine and inactivated vaccine are administered within 7 days prior to experimental vaccine inoculation, live attenuated vaccine shall be administered within 14 days prior to experimental vaccine inoculation;
12. Lactating women or pregnant women (including women of childbearing age with positive urine pregnancy test);
13. Those who have participated in or are participating in clinical trials related to COVID-19, or are participating in clinical trials of other drugs, or have received COVID-19 vaccines; The Investigator believes that the subject has any disease or condition that may place the subject at unacceptable risk; Subjects cannot meet the requirements of the program; Conditions that interfere with the assessment of vaccine response.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tao Huang
Role: PRINCIPAL_INVESTIGATOR
Hunan Provincial Center for Disease Control and Prevention
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hunan Provincial Center for Disease Control and Prevention
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIT-LKM-2021-NCV01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.